Research progarmme: statin safety therapeutics - PharmahungaryAlternative Names: Statin safety project - Pharmahungary
Latest Information Update: 05 Jul 2016
At a glance
- Originator Pharmahungary Group
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Atherosclerosis
Most Recent Events
- 05 Jul 2016 Investigation in Atherosclerosis in Hungary (unspecified route)
- 05 Jul 2016 Research progarmme: statin safety therapeutics - Pharmahungary is available for licensing - http://www.pharmahungary.com/in-house-r-d-projects